| scholarly article | Q13442814 |
| P50 | author | Deirdre A Lane | Q87919930 |
| Mikhail S. Dzeshka | Q50123563 | ||
| Gregory Lip | Q60393087 | ||
| P2860 | cites work | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin | Q28171104 |
| Antithrombotic therapy in atrial fibrillation | Q28175172 | ||
| Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation | Q28201331 | ||
| Independent predictors of stroke in patients with atrial fibrillation: a systematic review | Q28219197 | ||
| Validation of Clinical Classification Schemes for Predicting Stroke | Q29028208 | ||
| Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators | Q33863941 | ||
| A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey | Q34105149 | ||
| A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice | Q34146593 | ||
| A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study | Q34200483 | ||
| A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study | Q34225539 | ||
| Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. | Q34395380 | ||
| Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease | Q86719687 | ||
| Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study | Q34540479 | ||
| Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies | Q34585334 | ||
| Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788530 | ||
| Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation | Q35003773 | ||
| Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study | Q36001150 | ||
| Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2 | Q36051330 | ||
| Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study | Q36255692 | ||
| Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation | Q36501853 | ||
| Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. | Q36738148 | ||
| Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study | Q36811082 | ||
| A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score | Q36974348 | ||
| Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute | Q37417065 | ||
| The net clinical benefit of warfarin anticoagulation in atrial fibrillation | Q37421352 | ||
| Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis | Q37868373 | ||
| Can we predict stroke in atrial fibrillation? | Q37975986 | ||
| Can we predict the occurrence of atrial fibrillation? | Q37975988 | ||
| Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control | Q37995402 | ||
| Stroke and thromboembolism in atrial fibrillation | Q38045737 | ||
| Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? | Q38069057 | ||
| Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin | Q38075841 | ||
| Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants. | Q38097388 | ||
| Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey. | Q38106663 | ||
| Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. | Q38161519 | ||
| Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin | Q38460198 | ||
| Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. | Q39481700 | ||
| Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study | Q42616959 | ||
| Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort | Q42850914 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. | Q43215340 | ||
| Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry | Q43576468 | ||
| Barriers to warfarin use for stroke prevention in patients with atrial fibrillation in Hong Kong | Q43811395 | ||
| Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study | Q43814544 | ||
| Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). | Q43840992 | ||
| Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study | Q44104897 | ||
| Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. | Q44405113 | ||
| Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation | Q44414540 | ||
| Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation | Q44704577 | ||
| Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study | Q44764166 | ||
| Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study | Q45343563 | ||
| Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direc | Q46039081 | ||
| Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators | Q46139300 | ||
| Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation | Q46142380 | ||
| Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control | Q46210612 | ||
| Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study | Q46610148 | ||
| Warfarin or novel oral anticoagulants for atrial fibrillation? | Q46666573 | ||
| Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. | Q47790299 | ||
| Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation | Q47890361 | ||
| The increasing incidence of anticoagulant-associated intracerebral hemorrhage | Q48315722 | ||
| The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe? | Q50112674 | ||
| Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective | Q50188024 | ||
| Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. | Q50234449 | ||
| Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. | Q50324470 | ||
| CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. | Q50480351 | ||
| Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. | Q50515419 | ||
| Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. | Q51243653 | ||
| Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). | Q51275198 | ||
| Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. | Q51363743 | ||
| Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. | Q51368043 | ||
| Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. | Q51449304 | ||
| Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. | Q52229885 | ||
| Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. | Q53146463 | ||
| The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. | Q55055928 | ||
| ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committ | Q56626176 | ||
| 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation | Q56986288 | ||
| Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme | Q57086723 | ||
| Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation | Q57252877 | ||
| Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort | Q57260385 | ||
| 2012 focused update of the ESC Guidelines for the management of atrial fibrillation | Q57312493 | ||
| Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting | Q57627371 | ||
| Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe | Q57914596 | ||
| New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs | Q59541701 | ||
| Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—A nation wide database analysis | Q61851021 | ||
| Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials | Q72030226 | ||
| Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials | Q74725371 | ||
| Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients | Q81670366 | ||
| Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation | Q83861555 | ||
| The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER) | Q83994919 | ||
| Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with | Q84713332 | ||
| Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? | Q86568193 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acronym | Q101244 |
| atrial fibrillation | Q815819 | ||
| P304 | page(s) | 634-644 | |
| P577 | publication date | 2014-08-28 | |
| P1433 | published in | Clinical Cardiology | Q4502312 |
| P1476 | title | Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more) | |
| P478 | volume | 37 |
| Q42580574 | A bridge too far? Findings of bridging anticoagulation use and outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). |
| Q39926845 | Bleeding Risk Profile in Patients With Symptomatic Peripheral Artery Disease |
| Q36101603 | Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case |
| Q35846377 | Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation |
| Q26787046 | Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities |
| Q50123510 | Direct oral anticoagulant reversal: how, when and issues faced |
| Q38630768 | Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation |
| Q40275970 | Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes |
| Q47849138 | No Evidence for an Association Between Renal Function and Serious Bleeding Events in Patients Treated With Coumarins: A Population-Based Study |
| Q50142620 | Oral Anticoagulation in Atrial Fibrillation: Development and Evaluation of a Mobile Health Application to Support Shared Decision-Making |
| Q38939453 | Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed |
| Q28067358 | Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed |
| Q38728028 | Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? |
| Q26784497 | The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis |
| Q36396649 | The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants |
Search more.